U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07224347) titled 'Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)' on Oct. 31.
Brief Summary: ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants. Although the ASPREE trial medication was ceased, the study activity was not stopped and ASPREE participants are continuing with scheduled visits and phone calls. An observational follow-up phase (ASPREE-XT), began in January, 2018. This will enable the monitoring of possible delayed effects of aspirin treatment, primarily on cancer incidence, metastases and mortality. In addition to monitoring the incidence of malignancy within the ASPREE cohort, ...